Clinical Observation on 46 Cases of Alzheimer’s Disease Treated with Yishen Bunao Tablet

Hu Jincheng Wang Xnejun Zhu Chengquan

doi:10.13288/j.11-2166/r.2005.09.016

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on 46 Cases of Alzheimer’s Disease Treated with Yishen Bunao Tablet

更新时间：2021-11-20

- Clinical Observation on 46 Cases of Alzheimer’s Disease Treated with Yishen Bunao Tablet
- Journal of Traditional Chinese Medicine Issue 9, Pages: 670-672(2005)
- 作者机构：
  
  1. 广东省佛山市南海区中医院神经内科
  2. 暨南大学医学院中医系
  3. 中国人民解放军第四二一医院中医科广东省佛山市南海区桂城南五路16号,528200
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2005.09.016
  CLC： R277.7
- Published：2005
- 稿件说明：
移动端阅览
[1]胡金城,汪学军,朱成全.益肾补脑片治疗老年性痴呆46例临床观察[J].中医杂志,2005(09):670-672.

Hu Jincheng Wang Xnejun Zhu Chengquan. Clinical Observation on 46 Cases of Alzheimer’s Disease Treated with Yishen Bunao Tablet[J]. Journal of Traditional Chinese Medicine2005, (9): 670-672.
[1]胡金城,汪学军,朱成全.益肾补脑片治疗老年性痴呆46例临床观察[J].中医杂志,2005(09):670-672. DOI： 10.13288/j.11-2166/r.2005.09.016.

Hu Jincheng Wang Xnejun Zhu Chengquan. Clinical Observation on 46 Cases of Alzheimer’s Disease Treated with Yishen Bunao Tablet[J]. Journal of Traditional Chinese Medicine2005, (9): 670-672. DOI： 10.13288/j.11-2166/r.2005.09.016.

摘要

目的:探讨益肾补脑片对老年性痴呆（AD）的疗效。方法:将91例 AD 患者随机分为治疗组46例

给予益肾补脑片治疗;对照组45例

给予石杉碱甲片治疗。观察治疗前后两组临床疗效

检测超氧化物歧化酶（SOD）、丙二醛（MDA）、一氧化氮（NO）等的变化情况。结果:两组总体疗效差异无显著性;治疗组治疗后语言理解及命令服从计分较治疗前显著提高（P<0.05或 P<0.01）

对照组治疗后各主要症状计分虽有改善

但与治疗前比较差异无显著性（P>0.05）。治疗组治疗后 SOD 明显上升

MDA 和 NO 明显下降（P<0.01）

且 SOD、MDA 的变化较对照组明显（P<0.01）。结论:益肾补脑片可促进 AD 患者智能康复

提高 AD 患者生活质量

其近期疗效可能优于石杉碱甲片。

Abstract

Objective:To investigate the effect of Yishen Bunao Tablet on Alzheimer’s Disease（AD）.Methods:91 cases of AD were randomly divided into a treatment group（n=46）treated with Yishen Bunao Tablet and a control group（n=45）treated with huperzine A. Their clinical therapeutic effects

changes of superoxide dismutase（SOD）activity

malondialdehyde（MDA）and nitric oxide（NO） contents before and after treatment were determined.Results:There was no significant difference between the two groups in the total therapeutic effect;After treatment

the scores for language comprehend and order obey in the treatment group increased significantly（P<0.05 or P<0.01）;After treatment

the scores for main symptoms improved but with no significant difference in the control group（P>0.05）.SOD activity increased significantly

and contents of MDA and NO decreased significantly in the control group（P<0.01）

and the changes of SOD and MDA were more significant in the treatment group than those in the control group（P<0.01）.Conclusion:Yishen Bunao Tablet can promote intelligence recovery and increase quality of life for the patient of AD

and the shot-term therapeutic effect is better than that of huperzine A.

关键词

Keywords

references

查看原文

Views

196

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A Follow-up Study on Jinsiwei in Improving Hypomnesis in the Elderly with Questionable Dementia in Community

Construction and Application of "Source-Pivot-Convergence" Pattern Identification and Treatment Model for Malignant Tumors

Research on the Correlation Between "Tiangui （天癸）" and Female Reproductive Genetic Diseases

Exploration on the Connotation and Application of the Three Aspects of "Dietary Inquiry" for "Appetite" "Eating Capacity" "Food Preference"

WANG Qingguo's Experience in Treatment of Headache Based on the Concept of "Achieving Harmony by Unblocking and Balancing"

Related Author

Zhu Aihua

Tian Jinzhou

Zhong Jian

et al.

时晶

尹军祥

Related Institution

Dongzhimen Hospital of Beijing University of TCM

北京中医药大学东直门医院老年病科北京市东直门内海运仓5号

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰